Best Life Sciences Companies in Salt Lake City, United States
The 152 best Life Sciences companies in Salt Lake City, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Sera Prognostics.
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Salt Lake City
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Sera Prognostics Developer of biomarker-based tests for pregnancy care | $258M | 62 mo ago | 123 123 → 80 (-35%) | 2008 | Gregory Critchfield CEO | 127 patents Predictive protein/biomarker assays for pregnancy timing and complications | — |
| 2 | Varex Developer of imaging equipment and accessories | $175M | 72 mo ago | 2,400 | 2017 | — | — | — |
| 3 | MasterControl 🦄 Developer of software for quality, manufacturing, and asset management solutions | $150M | 42 mo ago | 560 | 1994 | — | 19 patents Enterprise software compliance automation and AI-driven knowledge graph/text analytics solutions. | — |
| 4 | biofire diagnostics BioFire Diagnostics is a biotech company that detects pathogens and mutations for molecular diagnostics. | $84M | 43 mo ago | 848 | 1990 | — | 227 patents Integrated rapid cell lysis and nucleic‑acid extraction for point‑of‑care infectious diagnostics | — |
| 5 | DiscGenics Developer of tissue engineering technology to treat patients debilitated by degenerative disc disease | $71M | 69 mo ago | 45 45 → 41 (-9%) | 2008 | Flagg Flanagan Chief Executive Officer & Chairman of the Board | 89 patents Regenerative intervertebral disc cell therapies, isolation, cryopreservation, and delivery devices. | 1 launch |
| 6 | Lineagen Sequencing-based diagnostic test and consultative services for autism | $67M | 136 mo ago | 40 | 2002 | — | 85 patents Genetic biomarkers and diagnostic tests for autism, developmental delays, and seizure disorders | — |
| 7 | Clene Nanomedicine Developer of therapeutics for the treatment of neurodegenerative diseases 29Funding top 29%Patents top 36%Tech top 41%Innovation top 47% All 10 signals ▾Fundingtop 29% Patentstop 36% Techtop 41% Innovationtop 47% Growthbottom 49% Moatbottom 44% Globalbottom 42% Marketbottom 32% Newsbottom 32% Fin. healthbottom 15% Funding: Raised $59.1M across 8 rounds · 8 rounds over 7 yrs (1.1/yr) Patents: 78 patents matched (strict assignee match) · 10 filings since 2022 vs 60 in 2017-21 rank vs industry peers · Fliar Intelligence Index 29/100 | $59M | 20 mo ago | 99 | 2012 | — | 78 patents Continuous nanomaterial synthesis and gold nanocrystal production for neuroregenerative therapies | — |
| 8 | Carterra Developer of a SPR based platforms to study enzyme kinetics | $45M | 30 mo ago | 84 | 2004 | Christian Giddens Director Of Sales | 15 patents High-throughput microfluidic scanning and biomolecular interaction analysis platforms | — |
| 9 | Foldax Developer of bio-polymeric heart valves to treat aortic, mitral, and tricuspid valve diseases | $44M | 32 mo ago | 46 | 2006 | Mory Gharib Co-Founder | 82 patents Manufacturing, material design, and delivery systems for implantable prosthetic heart valves | 1 job opening · 1 launch |
| 10 | PolarityTE Developer of regenerative medicine | $42M | 25 mo ago | 37 | 1998 | — | 63 patents Patents concentrated in chemistry & materials | — |
| 11 | Elevar Therapeutics Developer of therapeutic agents for treating cancer | $40M | 85 mo ago | 87 | 2005 | Alex Kim CEO | — | — |
| 12 | Lipocine Develops oral versions of hormones using Hydroance drug delivery technology | $38M | 154 mo ago | 17 17 → 24 (+41%) | 1997 | — | 366 patents Oral steroid formulations for hormonal, CNS, and liver disease therapies | 1 launch |
| 13 | Navigen Pharmaceuticals Peptide and small molecule therapeutics for infectious diseases | $34M | 84 mo ago | 22 | 2007 | — | — | — |
| 14 | Biofire Defense Biological agent identification products and services for biodefense and first responders | $34M | 142 mo ago | 150 | 1990 | Randy Rasmussen Co-Founder & CEO | 191 patents Rapid on-site nucleic acid testing and fast PCR molecular diagnostics solutions. | 2 launchs · 1 partnership |
| 15 | Techniscan Medical Systems Innovating medical imaging with advanced breast ultrasound technology | $31M | 186 mo ago | — | 1986 | David Borup Founder | — | — |
| 16 | IDbyDNA Developer of search engine to identify pathogens in sample | $29M | 76 mo ago | 75 | 2014 | — | 27 patents Targeted metagenomic sequencing and microbial identification for antimicrobial resistance profiling | — |
| 17 | Great Basin Scientific Sample-to-Result molecular diagnostics devices company | $28M | 119 mo ago | 182 | 2005 | — | — | — |
| 18 | Coherex Implant for structural heart disease conditions | $25M | 202 mo ago | 26 | 2003 | — | — | — |
| 19 | Second Heart A minimally invasive circulatory support platform | $24M | 53 mo ago | 5 | 2015 | Howard Leonhardt Co-Founder | 25 patents Implantable ventricular assist pumps and wireless power‑transfer circulatory support systems. | — |
| 20 | Blackrock Neurotech Developer of medical devices for neurological therapies | $22M | 13 mo ago | 127 127 → 191 (+50%) | 2008 | Florian Solzbacher Co-Founder & CSO | — | — |
| 21 | Kiora Pharmaceuticals Developer of therapies for the treatment of different types of eye diseases | $20M | 2 mo ago | 12 12 → 17 (+42%) | 2013 | Brian Strem CEO | — | 1 launch |
| 22 | MARAbio Developer of blood test for detecting maternal autoantibody-related autism | $19M | 21 mo ago | 4 | 2016 | Judy Water Co-Founder | — | — |
| 23 | Boka Sciences Provider of saliva-based real time health monitoring devices | $18M | 72 mo ago | 5 | 2008 | Porter Jones CEO | — | — |
| 24 | Q Therapeutics Cellular therapeutics company developing innovative therapies for incurable central nervous system diseases | $15M | 193 mo ago | 3 | 2004 | — | 1,872 patents Targeted protein degraders (PROTACs) and exosome-based therapeutics for oncology and neurodegeneration | — |
| 25 | CoNextions Medical Implant for the repair of tendons | $14M | 64 mo ago | 13 13 → 9 (-31%) | 2011 | — | — | — |
| 26 | Seek Labs Developer of a technology for the treatment and diagnostics of infectious diseases. 53AI top 15%Patents top 27%Innovation top 28%Moat top 32% All 9 signals ▾AItop 15% Patentstop 27% Innovationtop 28% Moattop 32% Fundingtop 33% Talentbottom 49% Techbottom 44% Globalbottom 31% Marketbottom 29% AI: Holds AI/ML patents (G06N-family CPC) Patents: 48 patents matched (strict assignee match) · 30 filings since 2022 vs 12 in 2017-21 rank vs industry peers · Fliar Intelligence Index 53/100 | $14M | 4 mo ago | 27 | 2017 | Jared Bauer CEO | 48 patents Molecular diagnostics and CRISPR-based nucleic acid testing for veterinary disease detection | — |
| 27 | Epitel Provider of a wearable EEG recording system for epilepsy monitoring and control 53Moat top 25%Innovation top 27%Patents top 28%Funding top 34% All 10 signals ▾Moattop 25% Innovationtop 27% Patentstop 28% Fundingtop 34% Growthtop 35% Talentbottom 49% Techbottom 47% Globalbottom 40% Marketbottom 32% Newsbottom 18% Moat: Editorial + unicorn rating 7/10 · IP moat: 56 patents Innovation: 56 patents (top 28% of patent-holders) · 47 filings since 2022 vs 9 in 2017-21 rank vs industry peers · Fliar Intelligence Index 53/100 | $12M | 10 mo ago | 39 | 2007 | Mark Lehmkuhle Founder & CEO | 56 patents AI-driven EEG monitoring devices for seizure detection and neurodiagnostic analytics | 1 launch · 1 award |
| 28 | Fluidx Medical Technology Developer of an embolic device to control vascular occlusion | $12M | 26 mo ago | 6 | 2015 | Lawrence Kronick Co-Founder | — | 3 launchs · 1 award |
| 29 | Xenocor Provider of Laparoscopic imaging system for surgeries | $10M | 39 mo ago | 11 | 2000 | Ashok Khandkar CEO | 32 patents Patents concentrated in computing, sensing & instrumentation | — |
| 30 | Sport Endurance Developer of capsule-based supplements for health and wellness | $9M | 90 mo ago | 31 | 2009 | — | — | — |
| 31 | Inherent Biosciences Developer of epigenetic diagnostics and therapeutics for complex diseases | $9M | 14 mo ago | 15 | 2019 | Kristin Brogaard Co-Founder & CSO | — | — |
| 32 | Remedy Informatics Clinical registries, research management software, and research informatics products | $8M | 163 mo ago | 51 | 2003 | — | — | — |
| 33 | Juneau Biosciences Diagnostics for women's health using population genetics and genomics | $8M | 162 mo ago | 12 | 2007 | Kenneth Ward Founder and CEO | — | — |
| 34 | DualCap Vascular access products for disinfection of IV lines and related accessories | $8M | 166 mo ago | 2,709 | 2008 | John Shannon CEO | — | — |
| 35 | Known Medicine Provider of drug response predictions using living patient cells and biomarkers | $7M | 57 mo ago | 15 | 2020 | Andrea Mazzocchi Co-Founder & CEO | — | — |
| 36 | World Heart Corporation Implantable ventricular assist devices for adults, children, and infants | $7M | 140 mo ago | 6 | 1996 | — | 51 patents Percutaneous ventricular assist device cannula rings and rotary blood pump control diagnostics | — |
| 37 | Rebel Medicine Developer of therapeutics for pain management | $7M | 16 mo ago | 9 | 2018 | — | 18 patents Analgesic drug formulations, especially oil‑in‑water emulsions for pain relief | — |
| 38 | Echelon Biosciences Lipid and cell signaling solutions for diagnostics and drug treatments | $7M | 21 mo ago | 20 | 1997 | Jeremy Amberson President and CEO | — | 3 launchs |
| 39 | ProLung Early-stage lung cancer risk test based on bioconductance technology | $6M | 72 mo ago | 6 | 2004 | Steven Eror Co-Founder & CEO | 2 patents Electrical grounding resistance monitoring and lung cancer diagnostic methods | — |
| 40 | Curza Developing novel antibiotics to combat antibiotic resistance and infectious diseases | $6M | 13 mo ago | 15 | 2007 | — | 70 patents Novel antimicrobial agents for crop protection and human therapeutics. | — |
| 41 | BioMicro Systems Developer of research products based on its proprietary microfluidic and microarray technologies | $5M | 224 mo ago | 10 | 2000 | — | — | — |
| 42 | Vital Access Needle guide - vascular access ports and tissue management apparatus | $5M | 132 mo ago | 14 | 2006 | — | 36 patents Subcutaneous vascular access port devices and implantation/attachment technologies for medical access | — |
| 43 | Larada Sciences Leading head lice treatment clinics offering fast, safe, effective solutions | $4M | 142 mo ago | 1 | 2006 | Larry Rigby Co-Founder | — | — |
| 44 | Co-Dx Provider of genomics-based information and solutions for transplant patients | $4M | 35 mo ago | 155 | 2013 | Dwight Egan CEO | — | — |
| 45 | 3Helix Developer of reagents that specifically bind denatured collagen | $4M | 31 mo ago | 8 | 2015 | Yang Li Founder & CEO | 26 patents Collagen‑targeted therapeutic peptides and fibrosis detection diagnostics | — |
| 46 | iVeena Delivery Systems Ophthalmology company developing disease-modifying eye drops for keratoconus and myopia | $3M | 16 mo ago | 6 | 2012 | — | — | — |
| 47 | ReddyPort Innovative oral care and communication solutions for non-invasive ventilation (NIV) patients | $3M | 8 mo ago | 6 | 2015 | Tony Lair CEO | 10 patents Advanced positive‑pressure ventilation devices and integrated monitoring accessories for respiratory care | — |
| 48 | Sethera Therapeutics Provider of peptide-based drug discovery platform | $2M | 20 mo ago | — | 2024 | Alyson Lord Co-Founder | — | — |
| 49 | Co-Diagnostics Provider of statistical bioinformatics-based molecular diagnostics | $2M | 35 mo ago | 155 155 → 87 (-44%) | 2012 | Dwight Egan Co-Founder & CEO | 94 patents Cooperative primer technologies for enhanced nucleic‑acid variant detection and infection diagnostics | 2 partnerships · 1 expansion |
| 50 | Applied Biosensors Wireless telemetry system for continuous multi-analyte monitoring | $675K | 34 mo ago | 5 | 2013 | Prashant Tathireddy Founder and Chief Executive Officer | — | — |
Top 12 Life Sciences companies in Salt Lake City
#1
Public · Salt Lake City, Utah · founded 2013 · 12 employees$20.2Mraised▾
Developer of therapies for the treatment of different types of eye diseases. The company lead product candidate KIO-301 is a molecular photoswitch that has the potential to restore light perception in patients with inherited and age-related retinal degeneration. Other drug candidates include KIO-101 for Dry Eye Disease, KIO-201 for PRK surgical recovery, and KIO-102 (Oral) for autoimmune diseases.
- Apr 2026Post IPO$5M
- Jan 2024Post IPO$15M
- Feb 2023Post IPO$200K
#2
Series B · Salt Lake City, Utah · founded 2017 · 27 employees$13.6Mraised▾
Developer of a technology for the treatment and diagnostics of infectious diseases. It offers point-of-care diagnostic and clustered regularly interspaced short palindromic repeats (CRISPR)-based technologies to detect and treat infectious diseases.
- Feb 2026Grant (prize money)$2M
- Aug 2023Series B$13.6M
#3
Series A · Salt Lake City, Utah · founded 2007 · 39 employees$12.5Mraised▾
Provider of a wearable EEG recording system for epilepsy monitoring and control. It offers a scalp wearable medical-grade seizure monitoring system. The rechargeable device can be applied to the scalp by an adhesive and can be worn irrespective of time and location. The device is paired via Bluetooth with a mobile application that detects and records seizures. The obtained data can be then used by a doctor to optimize one's treatment and lifestyle.
- Aug 2025Grant (prize money)$6.3M
- Apr 2025Grant (prize money)$3.4M
- Feb 2022Series A$12.5M
- Dec 2019Seed—
#4
Acquired · Salt Lake City, Utah · founded 2008 · 127 employees$22.4Mraised▾
Developer of medical devices for neurological therapies
- May 2025Grant (prize money)$969.7K
- Mar 2025Grant (prize money)$969.7K
- Apr 2024Series B$12.4M
- Sep 2023Grant (prize money)$1.5M
#5
Public · Salt Lake City, Utah · founded 2012 · 99 employees$59.1Mraised▾
Developer of therapeutics for the treatment of neurodegenerative diseases. The company focused on revolutionizing the treatment of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). Their approach centers on developing novel clean-surfaced nanotechnology therapeutics that target cellular energy impairments common in these diseases to restore and protect neuronal health and function.
- Oct 2024Post IPO$7.3M
- Dec 2021Grant (prize money)$1M
- May 2021Post IPO$9.2M
- Aug 2020Series D$42.5M
#6
Series A · Salt Lake City, Utah · founded 2015 · 6 employees$2.9Mraised▾
Innovative oral care and communication solutions for non-invasive ventilation (NIV) patients. They provide solutions that enable oral access for moisture relief and oral care for BiPAP patients without mask removal. Their system allows clinicians to provide dry mouth relief, routine oral care, and effective communication without BiPAP mask removal. This easy-to-use tool can be used by caregivers, patients, or family members to deliver compliant oral care. They focus on NV-HAP mitigation, offering resources and education to improve patient outcomes and reduce hospital-acquired pneumonia risks. Their products support better workflows and enhance the quality of care for NIV patients. They offer NIV Oral Care Kits, components, and a microphone.
- Oct 2025Series A$251.9K
- Nov 2023Series A$2.5M
- Jun 2018Seed$400K
#7
Series A · Salt Lake City, Utah · founded 2019 · 15 employees$9.1Mraised▾
Developer of epigenetic diagnostics and therapeutics for complex diseases. It focuses on identifying dysregulation across multiple genes and related pathways. It aims to transform the diagnosis and treatment of complex diseases like infertility through its epigenetic platform. The company's initial product, SpermQT, seeks to improve fertility testing and provide personalized treatment plans.
- Apr 2025Grant (prize money)$1.9M
- Feb 2025Grant (prize money)$1.9M
- Jan 2025Grant (prize money)$1.9M
- Feb 2024Grant (prize money)$1M
#8
Series A · Salt Lake City, Utah · founded 2007 · 15 employees$5.6Mraised▾
Developing novel antibiotics to combat antibiotic resistance and infectious diseases. This is a small-molecule therapeutics company focused on infectious diseases, developing structurally distinct classes of proprietary drugs. The company aims to combat the rising epidemic of antibiotic resistance by developing novel antibiotic classes. Their lead program targets drug-resistant Gram-negative bacteria, specifically ESKAPE pathogens, using an unexploited binding site of the bacterial ribosome. They are also developing novel antibiotics for ESKAPE pathogens or "superbugs" and antibiofilm antibiotics to treat biofilm-related infections. This is a B2B tech company focused on pharmaceutical research and development.
- Apr 2025Grant (prize money)$2M
- Apr 2025Grant (prize money)$2M
- Jul 2024Grant (prize money)$1M
- May 2024Grant (prize money)$1000K
#9
Series A · Salt Lake City, Utah · founded 2018 · 9 employees$7.2Mraised▾
Developer of therapeutics for pain management. It offers Alevatrx injectable local anesthetic formulation for postoperative pain and Alevaderm is a local anesthetic wound dressing for painful dermal injuries.
- Feb 2025Series A$6.1M
- Jan 2025Grant (prize money)$295.9K
- Sep 2024Grant (prize money)$295.9K
- Sep 2021Grant (prize money)$263.1K
#10
Series A · Salt Lake City, Utah · founded 2016 · 4 employees$19.1Mraised▾
Developer of blood test for detecting maternal autoantibody-related autism. The company's precision technology uses a blood test in women to identify the presence of a distinct cluster of autoantibodies that lead to Maternal Autoantibody Related Autism thereby enabling the earliest risk assessment for the development of autism in a child.
- Sep 2024Series A$19.1M
#11
Series B · Salt Lake City, Utah · founded 2012 · 6 employees$3.4Mraised▾
Ophthalmology company developing disease-modifying eye drops for keratoconus and myopia. This clinical-stage biopharmaceutical company focuses on innovative pharmacologic treatments for refractive diseases. Their lead programs consist of novel proprietary eye drops, including an Orphan Drug Designated treatment for keratoconus and a first-in-class investigational eyedrop formulation for pediatric myopia. They are committed to advancing treatments for these target conditions through clinical trials and research. The company is dedicated to creating advancements in eye care through the development of novel therapeutics. Their pipeline reflects a commitment to addressing unmet needs in ophthalmology.
- Feb 2025Series B$3M
- Sep 2023Grant (prize money)$345K
- Sep 2020Grant (prize money)$1.7M
- Jul 2020Series A$2.1M
#12
Acquired · Salt Lake City, Utah · founded 1997 · 20 employees$7.1Mraised▾
Lipid and cell signaling solutions for diagnostics and drug treatments. They develop research reagents and assays focused on lipid and cell signaling to advance diagnostics and drug treatments for debilitating diseases. They offer a comprehensive range of products including lipids, bioassays & kits, antibodies & proteins, peptides, and biochemical reagents. Services include assay services, LNP services, custom synthesis, and nanobody production. Their mission is to empower scientific discovery by providing high-quality solutions in lipid synthesis, formulation, and analysis. They collaborate with scientists, providing expert insight and dedicated support to accelerate breakthroughs. They are committed to social responsibility, fostering a sustainable future, supporting diversity & inclusion, environmental stewardship, and ethical business practices. They offer technical support, FAQs, and resources to assist researchers in their work.
- Sep 2024Grant (prize money)$399.3K
- Jan 2019Grant (prize money)$300K
- Aug 2014Grant (prize money)$224.3K
- Nov 2011Grant (prize money)$625.2K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in the United States
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 6,260 United States-affiliated papers.
- Harvard University209
- Cornell University177
- University of Tennessee at Chattanooga140
- Howard Hughes Medical Institute126
- Johns Hopkins University121
- Gene33→164
- Transcription (linguistics)11→79
- Antibody11→62
- Genome6→56
- Mutation7→56
- Gene8→110
- Cell culture3→62
- Gene expression3→62
- Fermentation2→54
- Downregulation and upregulation1→50
- Agriculture19→58
- Antibiotic resistance15→45
- Public health4→31
- Gene6→30
- Production (economics)5→29
Where biotechnology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing biotechnology patents in the United States
United States biotechnology patent filing is accelerating — 457,918 filings from 8,000 assignees (2016–2025), led by Genentech, UNIV California, Regeneron Pharma; annual filings 36884→44446.
- Genentech18078
- UNIV California17948
- Regeneron Pharma16082
- Amgen10495
- Monsanto Technology9742
- UNIV Pennsylvania8521
- Harvard College7460
- UNIV Texas7378
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.